HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment

scientific article published on November 2013

HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/ADM.0B013E3182A3B603
P698PubMed publication ID24189173

P50authorDavid A. FiellinQ38800653
Brent MooreQ39977499
E Jennifer EdelmanQ86191217
Lynn E. FiellinQ86575062
Kathleen J SikkemaQ92031876
Richard S SchottenfeldQ96038811
P2093author name stringSarah Caffrey
Emlyn S Jones
P433issue6
P304page(s)410-416
P577publication date2013-11-01
P1433published inJournal of Addiction MedicineQ15752435
P1476titleHIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment
P478volume7

Reverse relations

cites work (P2860)
Q38621655A mixed methods study of HIV-related services in buprenorphine treatment
Q33644060The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients

Search more.